CPT code 88299 designates an unlisted cytogenetic procedure for reporting cytogenetic services that lack a specific CPT code. This code is used nationally when laboratories perform nonstandard or novel cytogenetic analyses such as specialized karyotyping variations, advanced chromosome microarray techniques not otherwise specified, or other bespoke cytogenetic assays. Its use matters because unlisted codes require additional documentation and justification for medical necessity, affecting claims processing, reimbursement timelines, and prior authorization workflows.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find an overview of payer coverage considerations, typical billing and documentation expectations for unlisted cytogenetic reporting, and descriptions of where 88299 fits within cytogenetics service delivery. The publication summarizes common modifiers and administrative steps associated with unlisted procedure reporting, highlights clinical contexts that commonly generate unlisted cytogenetic claims, and outlines documentation elements payers typically request for adjudication.

This summary targets laboratory billing managers, medical coders, and compliance staff seeking a concise reference on 88299, including operational impacts on claims submission and the documentation needed to support medical necessity for atypical cytogenetic procedures. Data not available in the input.